Sclerosol Intrapleural Aerosol

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved January 1998

Specific Treatments:

malignant pleural effusions

General Information

Sclerosol Intrapleural Aerosol has been approved for the prevention of recurrence of malignant pleural effusions in symptomatic patients. Symptoms include chest pain, dyspnea, and coughing. It is to be administered by aerosol during thracoscopy or open thoracotomy.